Abstract
Background
The main goal of anti-HCV therapy in patients with decompensated (Child-Pugh B) cirrhosis not on a transplant waiting list is to achieve improvement in liver function and survival. Several studies have demonstrated acceptably high SVR rates, equivalent in Child-Pugh B patients, in individuals with decompensated cirrhosis, together with an effect of therapeutic viral clearance on liver function, with significant improvements in bilirubin, albumin and international normalized ratio values and, as a result, in MELD and Child-Pugh scores in one-third to half of patients. Similar results were reported in real-world studies. Patients with Child-Pugh B cirrhosis benefited more from viral clearance in terms of adverse event-free survival at 15 months than those with Child-Pugh C cirrhosis.
Aim of the Work
Assessment of the safety & efficacy of sofosbuvir/ ledipasvir in infected naïve and experienced HCV Egyptian patients with decompensated liver disease.
Patients and Method
This study was conducted on 100 patients with HCV related decompensated liver disease who presented to the hepatology outpatient clinic in El Agouza Police hospital and were evaluated according to the inclusion and exclusion criteria.
Conclusion
Ledipasvir/sofosbuvir is effective and safe in the treatment of HCV decompensated patients Child Pugh B. MELD and Child scores significantly improved with HCV treatment in decompensated patients
Recommendations
Longer follow up with assessment of the need for liver transplantation or HCC development is important. Larger number of patients is required.
P042 An audit of the knowledge of the decompensated liver disease bundle and ascitic taps on patients presenting on the medical take
